Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new gene therapy called SGT-212 for Friedreich's ataxia, a rare disease that affects how the body moves and coordinates. This is the first time this treatment is being tested in humans. The study will enroll 10 patients and follow them for about 5 years to see if the treatment is safe and works well.
WHY IT MATTERSThis is the first human trial of SGT-212 for Friedreich's ataxia, offering eligible patients access to a potentially disease-modifying gene therapy that addresses the underlying genetic cause rather than just managing symptoms.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for 1,500 people with inherited eye diseases caused by rare genetic changes to join a study. The study has two parts: first, they'll collect genetic information and eye health data from participants, and second, they'll follow some participants over time to understand how these eye diseases progress. This international study is now accepting new participants.
WHY IT MATTERSIf you have an inherited retinal disease with a rare genetic variant, enrolling in this registry could help researchers understand your condition better and speed up development of future treatments while contributing to a global database of genetic information.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for 20,000 people with rare diseases that doctors haven't been able to diagnose yet. Many patients spend years going to different doctors and getting repeated tests without finding answers. This study, run by the National Human Genome Research Institute, aims to help solve medical mysteries by using genetic testing and careful evaluation to figure out what's causing people's symptoms.
WHY IT MATTERSIf you or a family member has spent years seeking a diagnosis without answers, this large national study offers free genetic evaluation and expert medical review specifically designed to identify undiagnosed rare diseases.
ResearchCLINICALTRIALSMar 26
Boston Children's Hospital is looking for 10,000 families with rare genetic diseases that haven't been diagnosed or fully understood yet. Researchers will study the genes and proteins in these families to figure out what's causing their conditions. The goal is to help doctors diagnose and treat rare diseases better in the future.
WHY IT MATTERSIf your family has been searching for answers about a rare or undiagnosed genetic condition, this study could help identify what's causing it and contribute to better treatments for others with the same disease.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for people with melorheostosis, a rare disease where bones become abnormally thick and hard, to join a study. The study will follow participants over time to understand how the disease develops and what causes it. Doctors will do physical exams and collect medical information from people with the disease and their unaffected family members.
WHY IT MATTERSThis is an active recruiting trial sponsored by the National Institutes of Health that could help researchers understand melorheostosis progression and identify disease mechanisms, potentially leading to future treatments for this condition with limited research.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new genetic tool called RNA-Seq to help diagnose rare diseases in children and adults whose current genetic tests came back negative. This tool looks at how genes are turned on and off in cells, which can reveal problems that standard DNA testing misses. The study will first test the tool in healthy people and those with known genetic conditions, then use it to try to diagnose patients with undiagnosed rare diseases.
WHY IT MATTERSIf you have a child or family member with symptoms of a rare kidney or genetic disease but genetic testing hasn't found answers, this trial could offer a new diagnostic pathway that standard tests have missed.
ResearchCLINICALTRIALSMar 26
Researchers at St. Jude Children's Research Hospital are recruiting 385 people—including patients, families, doctors, and scientists—to share their thoughts about ethical questions that come up when testing new treatments for rare brain and nerve diseases. The study wants to understand what different groups of people think is fair and right when designing these small, personalized treatment trials.
WHY IT MATTERSThis study directly shapes how future rare neurological disease trials will be designed and conducted, meaning your input as a patient or caregiver could influence the ethical standards that protect you in future treatment studies.